Another option is the clinical Tempus xF panel that is to be used for molecular profiling of ctDNA and covers 105 genes (Tempus xF - Clinical test - NIH Genetic Testing Registry GTR - NCBI, 2023) including glioma marker DNA sequence alterations except of ATRX, CIC, FUBP1, and TERT-promoter (Genomic Profiling - Tempus, 2023). This evidence concerns the gene CIC and central nervous system cancer.